Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells

Cancer Research

Volumn 61, Issue 18, 2001, Pages 6747-6754

  Bartucci, Monica ^a,b   Morelli, Catia ^a,b   Mauro, Loredana ^a,b   Ando’, Sebastiano ^b   Surmacz, Eva ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRAIN MCF 7; ENZYME REGULATION; ENZYME SUBSTRATE; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MITOGENESIS; MITOSIS INDEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL DIVISION; CELL MOVEMENT; CELL SURVIVAL; ENZYME ACTIVATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035884617     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Function of the IGF-IR in breast cancer
2. The IGF-I receptor in cancer research
3. IGF-I: An essential factor in terminal end bud formation and ductal morphogenesis
4. IGF-I receptor and cyclin D1 expression influence cellular radiosensitivity and local breast cancer recurrence after lumpectomy and radiation
5. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer
6. Insulin-like growth factor binding protein 3 and insulin receptor substrate 1 in breast cancer: Correlation with clinical parameters and disease free survival
7. Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation or insulin receptor substrate-1 expression in vitro and in vivo
8. Circulating concentrations of insulin like growth factor and risk of breast cancer
9. Insulin-like growth factor I (IGF-I) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs
10. Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells
11. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - Proliferative and anti-apoptotic effects
12. Overexpression of IRS-1 in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation
13. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival and promote cell-cell adhesion in human breast cancer cells
14. A dominant negative mutant of the insulin-like growth factor I receptor inhibits the adhesion, invasion and metastasis of breast cancer
15. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid
16. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
17. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells
18. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer
19. Characterization of insulin-like growth factor I receptors (IGF-IR) in human breast cancer cell lines
20. Insulin and insulin-like growth factor signaling are defective in MDA-MB-468 human breast cancer cell line
21. IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells
22. The response of breast cancer cells to steroid and peptide growth factors
23. The roles of integrins and extracellular matrix proteins in the IGF-IR-stimulated chemotaxis of human breast cancer cells
24. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation
25. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
26. 1 integrin interactions regulate breast cancer cell adhesion and motility
27. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
28. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
29. p38 mitogen-activated protein kinase inhibitors - Mechanisms and therapeutic potentials
30. The IGF-IR in mitogenesis and transformation of mouse embryo fibroblasts: Role of receptor number
31. Molecular markers of IGF-I-mediated mitogenesis
32. Phosphoinositide3-kinase: The key switch mechanism in insulin signalling
33. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase
34. The PI3K-PDK1 connection: More than just a road to PKB
35. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38α mitogen-activated protein kinase activity
36. Prolonged activation of ERK2 by epidermal growth factor and other growth factors requires a functional insulin-like growth factor I receptor
37. The IRS-signalling system: A network of docking proteins that mediate insulin action
38. Multiple signaling pathways of the insulin-like growth factor I receptor in protection from apoptosis
39. Phosphorylation and regulation of Raf by Akt (protein kinase B)
40. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt
41. Insulin-like growth factor-I (IGF-I) receptors in breast cancer
42. Type 1 IGF receptor in human breast diseases
43. The prognostic value of insulin-like growth factor I in breast cancer. Results of a follow-up study on 126 patients
44. The activated insulin-like growth factor I receptor induces depolarization in breast cancer cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin
45. Insulin-resistant MDA-MB231 human breast cancer cells contain a tyrosine kinase inhibiting activity
46. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism
47. Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3′-kinase inhibition